MCID: HPT073
MIFTS: 72

Hepatitis C Virus

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis C Virus

MalaCards integrated aliases for Hepatitis C Virus:

Name: Hepatitis C Virus 58
Hepatitis C Virus, Susceptibility to 58 30 6 41
Hepatitis C Virus Infection, Response to Therapy of 58 30 6
Response to Antiviral Treatment in Hepatitis C 60
Hepatitis C Virus, Response to Therapy of 58
Response to Peg/ifn-Ribavirin in Hcv 60
Hepatitis C Virus, Resistance to 58
Resistance to Hepatitis C Virus 6
Hcv, Susceptibility to 58
Hcv 58

Classifications:



External Ids:

OMIM 58 609532
Orphanet 60 ORPHA284102

Summaries for Hepatitis C Virus

OMIM : 58 HCV, which is principally transmitted by blood, infects about 3% of the world's population. HCV infection causes acute hepatitis, which is self-resolving in 20 to 50% of cases but does not confer permanent immunity. In 50 to 80% of cases, HCV infection becomes chronic and results in chronic hepatitis, cirrhosis, and hepatocellular carcinoma. As a result, HCV infection is a leading killer worldwide and the most common cause of liver failure in the U.S. HCV is opportunistic in individuals infected with human immunodeficiency virus (HIV; see 609423), approximately 25% of whom are coinfected with HCV. HCV infection is also associated with cryoglobulinemia (see 123550), a B-lymphocyte proliferative disorder (Pawlotsky, 2004; Chisari (2005); Pileri et al., 1998). (609532)

MalaCards based summary : Hepatitis C Virus, also known as hepatitis c virus, susceptibility to, is related to hepatitis c and hepatitis. An important gene associated with Hepatitis C Virus is IFNG (Interferon Gamma), and among its related pathways/superpathways are JAK-STAT signaling pathway (KEGG) and Jak-Stat Signaling Pathway (sino). The drugs Tacrolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and testes, and related phenotypes are Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection and hematopoietic system

Related Diseases for Hepatitis C Virus

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis C Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 613)
# Related Disease Score Top Affiliating Genes
1 hepatitis c 33.8 CD81 CLDN1 CLDN6 CLDN9 CLEC4M GPT
2 hepatitis 33.1 CD81 CLDN1 CLDN6 CLDN9 GPT IFNL4
3 hepatitis d 31.1 GPT IFNL3
4 cryptogenic cirrhosis 30.9 KRT18 KRT8
5 nonalcoholic steatohepatitis 30.7 GPT KRT18
6 recurrent hepatitis c virus induced liver disease in liver transplant recipients 12.4
7 hepatocellular carcinoma 11.8
8 polyarteritis nodosa 11.6
9 fibrillary glomerulonephritis 11.2
10 gianotti crosti syndrome 11.2
11 immunotactoid glomerulopathy 11.2
12 immunotactoid or fibrillary glomerulopathy 11.2
13 noonan syndrome 3 11.2
14 cryoglobulinemia 10.9
15 hepatitis b 10.9
16 liver disease 10.9
17 liver cirrhosis 10.9
18 cryoglobulinemia, familial mixed 10.8
19 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.8
20 lichen planus 10.7
21 lymphoma 10.7
22 glomerulonephritis 10.7
23 noonan syndrome 2 10.6
24 vasculitis 10.6
25 membranoproliferative glomerulonephritis 10.6
26 diabetes mellitus, noninsulin-dependent 10.6
27 porphyria cutanea tarda 10.6
28 porphyria 10.6
29 oral lichen planus 10.6
30 kidney disease 10.5
31 neurenteric cyst 10.5 KRT18 KRT8
32 fatty liver disease, nonalcoholic 1 10.5
33 proliferating trichilemmal cyst 10.5 KRT18 KRT8
34 cutaneous adenocystic carcinoma 10.5 KRT18 KRT8
35 chronic kidney failure 10.5
36 autoimmune lymphoproliferative syndrome, type v 10.5
37 viral infectious disease 10.5 CCR5 CD81 GPT IFNG
38 human immunodeficiency virus type 1 10.5
39 thalassemia 10.5
40 cervical clear cell adenocarcinoma 10.5 KRT18 KRT8
41 autoimmune hepatitis 10.5
42 odontoma 10.5 KRT18 KRT8
43 diabetes mellitus 10.4
44 hemophilia 10.4
45 noonan syndrome 4 10.4
46 noonan syndrome 5 10.4
47 viral hepatitis 10.4
48 end stage renal failure 10.4
49 human immunodeficiency virus infectious disease 10.4
50 mucinous tubular and spindle renal cell carcinoma 10.4 KRT18 KRT8

Graphical network of the top 20 diseases related to Hepatitis C Virus:



Diseases related to Hepatitis C Virus

Symptoms & Phenotypes for Hepatitis C Virus

Clinical features from OMIM:

609532

GenomeRNAi Phenotypes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 9.02 CD81 CLDN1 GPT HM13 PNKD

MGI Mouse Phenotypes related to Hepatitis C Virus:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 ATG5 CCR5 CD81 CLEC4M HM13 IFNG
2 immune system MP:0005387 9.65 ATG5 CCR5 CD81 CLEC4M HM13 IFNG
3 liver/biliary system MP:0005370 9.23 ATG5 CCR5 HM13 IFNG KRT18 KRT8

Drugs & Therapeutics for Hepatitis C Virus

Drugs for Hepatitis C Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 617)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 6473866 445643 439492
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
4
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
5
Dopamine Approved Phase 4,Phase 3,Phase 2 62-31-7, 51-61-6 681
6
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 198153-51-4 5360545
7
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
8
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
9
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
10
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
11
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 215647-85-1, 99210-65-8
12
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
13
Methadone Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
14
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
15
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147127-20-6 464205
16
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 143491-57-0 60877
17
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
18
leucovorin Approved Phase 4,Phase 2,Phase 1 58-05-9 143 6006
19
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
20
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1190307-88-0 45375808
21
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1256388-51-8 67505836
22
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 154598-52-4 64139
23
Velpatasvir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1377049-84-7 67683363
24
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 32051
25
Insulin glulisine Approved Phase 4 207748-29-6
26
Insulin glargine Approved Phase 4 160337-95-1
27
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3 142217-69-4 153941
28
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 923604-59-5 66576988
29
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
30
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
31
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
32
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
33
Cobicistat Approved Phase 4,Phase 3,Phase 1 1004316-88-4
34
Iron Approved, Experimental Phase 4,Phase 2,Not Applicable 7439-89-6, 15438-31-0 27284 23925
35
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 134678-17-4 60825
36
Zidovudine Approved Phase 4,Phase 1,Phase 2 30516-87-1 35370
37
Interferon alfacon-1 Approved, Investigational Phase 4,Phase 3,Phase 2 118390-30-0 9554198
38
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 192725-17-0 92727
39
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179045-86-4, 152923-56-3
40
Nevirapine Approved Phase 4 129618-40-2 4463
41
Rifaximin Approved, Investigational Phase 4,Phase 2,Not Applicable 80621-81-4 46783403 6436173
42
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 1 376348-65-1 3002977
43
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 46835353 5284616 6436030
44
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 70789204 6442177
45
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
46
Losartan Approved Phase 4 114798-26-4 3961
47
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
48
Nelfinavir Approved Phase 4 159989-64-7 64143
49
Orlistat Approved, Investigational Phase 4,Not Applicable 96829-58-2 3034010
50
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771

Interventional clinical trials:

(show top 50) (show all 2389)
# Name Status NCT ID Phase Drugs
1 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
2 Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
3 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
4 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
5 Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC) Unknown status NCT02745132 Phase 4
6 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
7 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
8 Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
9 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
10 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
11 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
12 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
13 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
14 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
15 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
16 Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
17 PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
18 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
19 Nutritional Support During Antiviral Therapy for Hepatitis C Unknown status NCT00841243 Phase 4
20 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
21 Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection Unknown status NCT01147107 Phase 4 Raltegravir;Efavirenz
22 Endothelial Dysfunction and Subclinical Atheromatosis in Chronic HCV Infection. Response to DAA Agents. Unknown status NCT02802280 Phase 4
23 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
24 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
25 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
26 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
27 Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients Unknown status NCT00526448 Phase 4 ribavirin;ribavirin;Peginterferon alfa-2a;epoetin beta
28 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
29 Curing HCV in Incarcerated Patients Unknown status NCT03018353 Phase 4 Patients receiving Sof/Vel (Epclusa) and Navigation services
30 MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV Unknown status NCT03003338 Phase 4 OBV/PTV/r and DSV;Placebo to match OBV/PTV/r and DSV
31 Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
32 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
33 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
34 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
35 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
36 Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
37 Maraviroc Efficacy for Hepatitis C Completed NCT02881762 Phase 4 Maraviroc
38 Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus Completed NCT03961828 Phase 4 Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]
39 A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment Completed NCT03212521 Phase 4 glecaprevir/pibrentasvir
40 Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients Completed NCT01469884 Phase 4 Everolimus;Cyclosporine;Tacrolimus
41 Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation Completed NCT00821587 Phase 4 Cyclosporine;Tacrolimus
42 Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) Completed NCT02768961 Phase 4 sofosbuvir;ledipasvir
43 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
44 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
45 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) Completed NCT01134952 Phase 4 Mycophenolate to sirolimus switch
46 Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3 Completed NCT00143000 Phase 4 Peginterferon alfa-2a 40KD and Ribavirin
47 Australian Trial in Acute Hepatitis C Completed NCT00192569 Phase 4 Pegylated Interferon alfa 2a;Ribavirin (HIV conifected patients only)
48 The SIM-SOF Trial for Hepatitis C Completed NCT02168361 Phase 4 Pegylated Interferon alfa-2b;Simeprevir;Ribavirin;Sofosbuvir
49 Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World Completed NCT02964091 Phase 4 sofosbuvir/ledipasvir
50 Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C Completed NCT00938860 Phase 4 cyclosporin (Neoral);tacrolimus (Prograf)

Search NIH Clinical Center for Hepatitis C Virus

Genetic Tests for Hepatitis C Virus

Genetic tests related to Hepatitis C Virus:

# Genetic test Affiliating Genes
1 Hepatitis C Virus, Susceptibility to 30 CCR5 IFNG IFNL3 PTPRC
2 Hepatitis C Virus Infection, Response to Therapy of 30

Anatomical Context for Hepatitis C Virus

MalaCards organs/tissues related to Hepatitis C Virus:

42
Liver, Kidney, Testes, T Cells, B Cells, Heart, Bone

Publications for Hepatitis C Virus

Articles related to Hepatitis C Virus:

(show top 50) (show all 8451)
# Title Authors Year
1
Oral direct-acting antiviral therapy for hepatitis C virus infection in X-linked agammaglobulinemia. ( 30339854 )
2019
2
Healing of autoimmune hepatitis associated with hepatitis C virus infection treated with direct-acting antivirals. ( 30449122 )
2019
3
Occult hepatitis C virus infection in patients with beta-thalassemia major: Is it a neglected and unexplained phenomenon? ( 30775813 )
2019
4
Hepatitis C Virus Infection and Cholangiocarcinoma: An Insight into Epidemiologic Evidences and Hypothetical Mechanisms of Oncogenesis. ( 30953604 )
2019
5
Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis. ( 29857143 )
2019
6
Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. ( 30430284 )
2019
7
The dilemma of treating hepatitis C virus-associated cryoglobulinemia. ( 31090590 )
2019
8
Subacute cutaneous lupus erythematosus triggered by an antiviral treatment combination for hepatitis C virus infection. ( 30394571 )
2019
9
Prevalence of type 2 diabetes mellitus among hepatitis C virus-infected patients: a protocol for systematic review and meta-analysis. ( 30803444 )
2019
10
Dual Infection with Hepatitis B Virus and Hepatitis C Virus Correlated with Type 2 Diabetes Mellitus. ( 30654388 )
2019
11
Sustained Improvement in Type 2 Diabetes Mellitus is Common After Treatment of Hepatitis C Virus With Direct-acting Antiviral Therapy. ( 30614943 )
2019
12
Concomitant Treatment of Hepatitis C Virus and Diffuse Large B-Cell Lymphoma with Direct-Acting Antivirals in HIV Coinfection: A Case Report. ( 30798652 )
2019
13
Complete Response of Diffuse Large B Cell Lymphoma After Direct-Acting Antiviral Therapy for Hepatitis C Virus. ( 29432921 )
2019
14
Hepatitis C virus-induced glomerular disease and posterior reversible encephalopathy syndrome after liver transplant: Case report and literature review. ( 30804289 )
2019
15
Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients. ( 30839434 )
2019
16
Serum‑derived hepatitis C virus can infect human glioblastoma cell line SF268 and activate the PI3K‑Akt pathway. ( 30896873 )
2019
17
Regression of hepatitis C virus-associated membranoproliferative glomerulonephritis with direct-acting antiviral therapy after liver transplantation. ( 31033081 )
2019
18
Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection. ( 30798587 )
2019
19
Relationship between various hepatic function scores and the formation of esophageal varices in patients with HIV/hepatitis C virus co-infection due to contaminated blood products for hemophilia. ( 30358037 )
2019
20
Integrated care for methadone maintenance patients with hepatitis C virus infection. ( 31087764 )
2019
21
Infection of human pegivirus 2 (HPgV-2) is associated with hepatitis C virus but not hepatitis B virus infection in people who inject drugs. ( 31090532 )
2019
22
Association between hepatitis C virus and porphyria cutanea tarda. ( 31097365 )
2019
23
Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. ( 31100098 )
2019
24
Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6. ( 31108015 )
2019
25
Association of 32-bp deletion polymorphism and promoter methylation of PTEN and hepatitis C virus induced hepatocellular carcinoma. ( 31109254 )
2019
26
Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis. ( 31064176 )
2019
27
Hepatitis C virus 3b strains in injection drug users in Guangdong Province, China, may have originated in Yunnan Province. ( 31065852 )
2019
28
Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. ( 31067134 )
2019
29
The distribution and socioeconomic burden of Hepatitis C virus in South Australia: a cross-sectional study 2010-2016. ( 31068170 )
2019
30
Sam68 Promotes Hepatitis C Virus Replication by Interaction with Stem-Loop 2 of Viral 5' Untranslated Region. ( 31068419 )
2019
31
Broadly neutralizing antibodies targeting new sites of vulnerability in hepatitis C virus E1E2. ( 31068427 )
2019
32
Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. ( 31068655 )
2019
33
Differences across cyclophilin A orthologs contribute to the host range restriction of hepatitis C virus. ( 31074414 )
2019
34
CYP24A1 genetic variants in the vitamin D metabolic pathway are involved in the outcomes of hepatitis C virus infection among high-risk Chinese population. ( 31075507 )
2019
35
Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity. ( 31076402 )
2019
36
Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group. ( 31077527 )
2019
37
Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. ( 31078544 )
2019
38
Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. ( 31078622 )
2019
39
Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers. ( 31079356 )
2019
40
Human-rat chimeric anti-occludin monoclonal antibodies inhibit hepatitis C virus infection. ( 31079928 )
2019
41
Impact of non-selective beta blockers on portal hypertension and hepatic elasticity in hepatitis C virus-related liver cirrhosis. ( 31080201 )
2019
42
Experiences of diagnosis, stigma, culpability and disclosure in male patients with hepatitis C virus: An interpretative phenomenological analysis. ( 31081379 )
2019
43
25-Hydroxyvitamin D Inhibits Hepatitis C Virus Production in Hepatocellular Carcinoma Cell Line by a Vitamin D Receptor-Independent Mechanism. ( 31086078 )
2019
44
Molecular epidemiology of hepatitis C virus in Cambodia during 2016-2017. ( 31086236 )
2019
45
5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry. ( 31086268 )
2019
46
Flash Imaging Used in the Post-vascular Phase of Contrast-Enhanced Ultrasonography is Useful for Assessing the Progression in Patients with Hepatitis C Virus-Related Liver Disease. ( 31031037 )
2019
47
Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. ( 31031174 )
2019
48
Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort. ( 31033848 )
2019
49
Indelibly Stamped by Hepatitis C Virus Infection: Persistent Epigenetic Signatures Increasing Liver Cancer Risk. ( 31034828 )
2019
50
Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey. ( 31036011 )
2019

Variations for Hepatitis C Virus

ClinVar genetic disease variations for Hepatitis C Virus:

6 (show all 17)
# Gene Variation Type Significance SNP ID Assembly Location
1 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh37 Chromosome 3, 46414947: 46414978
2 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh38 Chromosome 3, 46373456: 46373487
3 PTPRC PTPRC, 77C-G single nucleotide variant risk factor
4 IFNG NM_000619.2(IFNG): c.-893C> G single nucleotide variant drug response rs2069707 GRCh38 Chromosome 12, 68160508: 68160508
5 IFNG NM_000619.2(IFNG): c.-893C> G single nucleotide variant drug response rs2069707 GRCh37 Chromosome 12, 68554288: 68554288
6 KRT18 NM_000224.2(KRT18): c.1230C> G (p.Thr410=) single nucleotide variant not provided rs386834225 GRCh37 Chromosome 12, 53346563: 53346563
7 KRT18 NM_000224.2(KRT18): c.1230C> G (p.Thr410=) single nucleotide variant not provided rs386834225 GRCh38 Chromosome 12, 52952779: 52952779
8 KRT18 NM_000224.2(KRT18): c.282C> T (p.Tyr94=) single nucleotide variant not provided rs386834224 GRCh37 Chromosome 12, 53343239: 53343239
9 KRT18 NM_000224.2(KRT18): c.282C> T (p.Tyr94=) single nucleotide variant not provided rs386834224 GRCh38 Chromosome 12, 52949455: 52949455
10 KRT18 NM_000224.2(KRT18): c.134G> C (p.Arg45Pro) single nucleotide variant not provided rs200221269 GRCh37 Chromosome 12, 53343091: 53343091
11 KRT18 NM_000224.2(KRT18): c.134G> C (p.Arg45Pro) single nucleotide variant not provided rs200221269 GRCh38 Chromosome 12, 52949307: 52949307
12 KRT8 NM_002273.3(KRT8): c.1033G> T (p.Ala345Ser) single nucleotide variant not provided rs386834221 GRCh37 Chromosome 12, 53292632: 53292632
13 KRT8 NM_002273.3(KRT8): c.1033G> T (p.Ala345Ser) single nucleotide variant not provided rs386834221 GRCh38 Chromosome 12, 52898848: 52898848
14 KRT8 NM_002273.3(KRT8): c.1340C> T (p.Ala447Val) single nucleotide variant not provided rs386834223 GRCh37 Chromosome 12, 53291324: 53291324
15 KRT8 NM_002273.3(KRT8): c.1340C> T (p.Ala447Val) single nucleotide variant not provided rs386834223 GRCh38 Chromosome 12, 52897540: 52897540
16 KRT8 NM_002273.3(KRT8): c.1412G> A (p.Gly471Glu) single nucleotide variant not provided rs386834222 GRCh37 Chromosome 12, 53291252: 53291252
17 KRT8 NM_002273.3(KRT8): c.1412G> A (p.Gly471Glu) single nucleotide variant not provided rs386834222 GRCh38 Chromosome 12, 52897468: 52897468

Cosmic variations for Hepatitis C Virus:

9 (show top 50) (show all 3365)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1626018 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 0
2 COSM1615665 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 0
3 COSM1602238 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 0
4 COSM6951673 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 0
5 COSM1616325 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 0
6 COSM3707827 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 0
7 COSM3707828 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 0
8 COSM1623051 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 0
9 COSM1612127 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 0
10 COSM1618451 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581L 4:145885684-145885684 0
11 COSM1611545 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 0
12 COSM1612685 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47V 19:52002156-52002156 0
13 COSM1612018 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 0
14 COSM1618219 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 0
15 COSM1624399 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 0
16 COSM1609798 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 0
17 COSM1605856 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 0
18 COSM1602404 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 0
19 COSM1607880 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221A 14:67807621-67807621 0
20 COSM3661787 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 0
21 COSM1270878 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 0
22 COSM1612900 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 0
23 COSM3663890 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 0
24 COSM6969923 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 0
25 COSM3717069 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 0
26 COSM6219678 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 0
27 COSM1613453 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 0
28 COSM3717124 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 0
29 COSM1608898 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 0
30 COSM3705381 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 0
31 COSM1601838 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 0
32 COSM1610770 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 0
33 COSM1601260 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 0
34 COSM1624206 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2136A>G p.T712T 8:80518852-80518852 0
35 COSM1624207 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2311A>G p.I771V 8:80519295-80519295 0
36 COSM1616586 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 0
37 COSM1624117 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1568A>G p.N523S 8:63187582-63187582 0
38 COSM1603361 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 0
39 COSM1617254 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167N 3:183722100-183722100 0
40 COSM3663693 XPO7 liver,NS,carcinoma,hepatocellular carcinoma c.806A>G p.Y269C 8:21977812-21977812 0
41 COSM1609152 XPO6 liver,NS,carcinoma,hepatocellular carcinoma c.882C>T p.G294G 16:28156289-28156289 0
42 COSM6957749 XPO1 liver,NS,carcinoma,hepatocellular carcinoma c.301+1G>C p.? 2:61522610-61522610 0
43 COSM1624082 XKR4 liver,NS,carcinoma,hepatocellular carcinoma c.1076A>G p.D359G 8:55523350-55523350 0
44 COSM1613650 XIRP2 liver,NS,carcinoma,hepatocellular carcinoma c.9350G>C p.R3117P 2:167250742-167250742 0
45 COSM3660541 XIRP1 liver,NS,carcinoma,hepatocellular carcinoma c.142C>A p.Q48K 3:39189304-39189304 0
46 COSM1625463 XIAP liver,NS,carcinoma,hepatocellular carcinoma c.493G>T p.A165S 23:123886155-123886155 0
47 COSM3663909 WWP1 liver,NS,carcinoma,hepatocellular carcinoma c.210-2A>G p.? 8:86381503-86381503 0
48 COSM1625309 WWC3 liver,NS,carcinoma,hepatocellular carcinoma c.1121C>A p.S374Y 23:10117180-10117180 0
49 COSM1621161 WTAP liver,NS,carcinoma,hepatocellular carcinoma c.283C>T p.Q95* 6:159748200-159748200 0
50 COSM6909096 WT1 liver,NS,carcinoma,hepatocellular carcinoma c.1019T>G p.L340* 11:32396283-32396283 0

Expression for Hepatitis C Virus

LifeMap Discovery
Genes differentially expressed in tissues of Hepatitis C Virus patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CXCL10 chemokine (C-X-C motif) ligand 10 Liver + 4.26 0.000
2 CXCL11 chemokine (C-X-C motif) ligand 11 Liver + 3.57 0.000
3 LOC553137 uncharacterized LOC553137 Liver - 3.21 0.000
4 CXCL9 chemokine (C-X-C motif) ligand 9 Liver + 3.07 0.000
Search GEO for disease gene expression data for Hepatitis C Virus.

Pathways for Hepatitis C Virus

Pathways related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.62 CCR5 IFNG IFNL3 PTPRC
2 11.28 CCR5 IFNG PTPRC
3 11.09 CLDN1 CLDN6 CLDN9 PTPRC

GO Terms for Hepatitis C Virus

Cellular components related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.86 ACY3 CD81 GPT KRT18 KRT8 PSMA7
2 bicellular tight junction GO:0005923 9.33 CLDN1 CLDN6 CLDN9
3 apicolateral plasma membrane GO:0016327 8.96 CLDN6 KRT8
4 cell periphery GO:0071944 8.8 KRT18 KRT8 PTPRC

Biological processes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.8 CCR5 CD81 IFNG PTPRC
2 defense response to virus GO:0051607 9.67 IFNG IFNL3 IFNL4 PTPRC
3 extrinsic apoptotic signaling pathway GO:0097191 9.5 IFNG KRT18 KRT8
4 hepatocyte apoptotic process GO:0097284 9.48 KRT18 KRT8
5 negative thymic T cell selection GO:0045060 9.46 ATG5 PTPRC
6 positive regulation of immune response GO:0050778 9.43 IFNL3 IFNL4
7 cell-cell junction organization GO:0045216 9.43 CLDN1 CLDN6 CLDN9
8 viral entry into host cell GO:0046718 9.43 CD81 CLDN1 CLDN6 CLDN9 CLEC4M SCARB1
9 regulation of phagocytosis GO:0050764 9.4 PTPRC SCARB1
10 viral process GO:0016032 9.4 ACY3 CCR5 CD81 CLDN1 CLDN6 CLDN9
11 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.33 CLDN1 CLDN6 CLDN9

Molecular functions related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.26 CLDN1 CLDN6 CLDN9 KRT18
2 virus receptor activity GO:0001618 9.17 CCR5 CD81 CLDN1 CLDN6 CLDN9 CLEC4M
3 protein binding GO:0005515 10.06 ACY3 ATG5 CCR5 CD81 CLDN1 CLDN6

Sources for Hepatitis C Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....